Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants (4sight)

10. november 2026 oppdatert av: GRIN Therapeutics, Inc.

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 1b Study With an Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function

This is a multinational, multicenter, randomized, double-blinded, placebo-controlled, Phase 1b study with an open-label extension (OLE) to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) in children with a genetic variant characterized as non-gain-of-function.

This study will consist of Part A (blinded, placebo-controlled) and Part B (blinded transition followed by an OLE).

Participants will be randomized in a 2:1 ratio to receive active drug (radiprodil) or matching placebo (Part A) and stratified by functional characterization (either indeterminant, LoF, or no effect). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.

The placebo-controlled portion is expected to be approximately 17 weeks for participants in Part A and at least 12 months for participants in Part B.

Studieoversikt

Detaljert beskrivelse

Participants are assigned in a 2:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Part B OLE.

This study is divided into the following parts:

Part A: Randomized, double-blind, placebo-controlled

  • Screening/Observation Period: To assess eligibility (approximately 5 weeks)
  • Titration Period (approximately 4 weeks): Titration of radiprodil or placebo to target dose
  • Maintenance Period (Part A): Target dose of radiprodil or placebo maintained for 8 weeks
  • Tapering and Follow-up Period: Gradual decrease and Follow-up Period for participants not entering Part B

Part B: Open-label safety follow-up period

  • Blinded Titration Period (approximately 4 weeks): Titration of radiprodil to target dose
  • Open-Label Treatment Period: Participants will continue to receive radiprodil until such time as either the participant withdraws/is withdrawn from the study, Sponsor terminates the study, or market access is available
  • Tapering and Follow-up Period: Gradual decrease and follow-up observation period for participants upon leaving the study

Studietype

Intervensjonell

Registrering (Antatt)

27

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 måned til 18 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Part A, Participant:

  • Diagnosed with GRIN-NDD with GRIN1, GRIN2A, GRIN2B, or GRIN2D gene variants known to result in a functional characterization that is loss of function, indeterminant, or no effect
  • Inadequately controlled seizures of any type with clinically significant EEG abnormalities per EEG collected within 12 months of Screening or during the Screening Period
  • Receiving at least 1 standard antiseizure medication (ASM)
  • On a stable dose of standard ASM for at least 4 weeks prior to screening and should remain on stable dose throughout study participation
  • Nonpharmacological treatments such as ketogenic diet should remain stable throughout study participation
  • Participant's caregivers are willing and able to complete entries in the eDiary on a daily basis and have demonstrated compliance

Part B, Participant:

- Has completed Part A and is eligible to continue study participation according to the judgment of the Investigator and Sponsor.

Exclusion Criteria:

PART A, Participant:

  • Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation or study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Is receiving >4 standard ASMs at screening
  • Has a body weight of less than 5 kg at screening
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.
  • Has clinically significant laboratory or ECG abnormalities according to the judgment of the Investigator or Sponsor
  • Has severe hepatic dysfunction (Child-Pugh grade C)
  • Has a history of brain surgery within 6 months of randomization for epilepsy or any other reason
  • Is receiving treatment with prohibited concomitant drugs such as agonists or antagonists of the glutamate receptor, including but not limited to felbamate, memantine, and perampanel
  • Is receiving treatment with a strong CYP3A4 inhibitor (eg, itraconazole or some antimicrobials that are strong inhibitors) that has not been discontinued at least 5 half-lives prior to the planned first dose of radiprodil
  • Has received any prior gene therapy
  • Is on treatment with hormonal therapy such as adrenocorticotrophic hormone or prednisolone

Part B Participant:

  • Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Participant or caregiver is unwilling or unable to comply with all study procedures for the duration of the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Radiprodil oral suspension

Liquid suspension of radiprodil, at varying concentrations depending on participant's weight.

The following dose-escalation regimen (twice daily [BID]) will be used:

Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose.

Radiprodil oral suspension

Placebo komparator: Placebo-to-match radiprodil oral suspension

Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen.

Placebo-to-match radiprodil oral suspension

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Adverse Events (AEs)
Tidsramme: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing adverse events (AEs). AEs will be assessed by frequency, type, severity, and duration. Treatment-emergent AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by System Organ Class and Preferred Term.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Serious Adverse Events (SAEs)
Tidsramme: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing serious adverse events (SAEs). SAEs will be assessed by frequency, type, severity, and duration, including treatment-emergent SAEs and SAEs considered related to investigational product.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Adverse Drug Reactions (ADRs)
Tidsramme: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).

Number and percentage of participants experiencing adverse drug reactions (ADRs). ADRs will be assessed by frequency, type, severity, and duration and summarized by functional characterization, study part, and overall.

From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
Change From Baseline in Blood Pressure
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in blood pressure (mmHg), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in Pulse Rate
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in pulse rate (beats per minute), assessed at scheduled study visits. Observed values and changes from Baseline will be summarized using descriptive statistics.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Physical Examination Findings
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants with abnormal physical or neurological examination findings. Findings will be listed, and findings indicative of adverse events will be included in adverse event summaries.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG Pulse Rate
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in pulse rate measured by 12-lead electrocardiogram (ECG), expressed in beats per minute (bpm).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG RR Interval
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the RR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG PR Interval
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the PR interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QRS Duration
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in QRS duration measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QT Interval
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the QT interval measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Change From Baseline in ECG QTcF Interval
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Change from Baseline in the QT interval corrected using Fridericia's formula (QTcF), measured by 12-lead electrocardiogram (ECG), expressed in milliseconds (ms).

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Clinically Significant Changes in Clinical Laboratory Parameters
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants with clinically significant abnormalities or changes in clinical laboratory parameters, including hematology, serum chemistry, and coagulation assessments. Laboratory values and changes from Baseline will be summarized, and clinically significant abnormal values listed separately.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Emergence of New Seizure Types
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing new seizure types compared with Baseline. Emergence of new seizure types will be tabulated overall and by seizure type at scheduled assessments.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Ideation
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing suicidal ideation at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
Occurrence of Suicidal Behavior
Tidsramme: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Number and percentage of participants experiencing suicidal behavior at any post-Baseline assessment, based on the Columbia-Suicide Severity Rating Scale (C-SSRS) or investigator assessment, as appropriate for the participant.

From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Plasma Concentration of Radiprodil
Tidsramme: From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).

Plasma concentrations of radiprodil will be measured at predefined pharmacokinetic (PK) sampling timepoints.

From first dose through study completion, including Part A (12 weeks of treatment) and Part B (anticipated at least 12 months).
Change From Baseline in SERIAS Green Light Days
Tidsramme: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of green light days, assessed using the Seizure-Related Impact Assessment Scale (SERIAS) and captured in the daily electronic diary (eDiary).

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Yellow Light Days
Tidsramme: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of yellow light days, assessed using SERIAS and captured in the daily eDiary.

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in SERIAS Red Light Days
Tidsramme: Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).

Change from Baseline to the end of the Part A Maintenance Period in the number of red light days, assessed using SERIAS and captured in the daily eDiary.

Baseline (4-week Observation Period) to the end of Part A Maintenance Period (Week 8).
Change From Baseline in Total Countable Seizure Frequency per 28 Days
Tidsramme: Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).

Change from Baseline in total countable seizure frequency normalized to 28 days during the Part A Maintenance Period (Weeks 1 through 8), as recorded in the daily seizure eDiary.

Baseline (last 4 weeks before randomization) through Part A Maintenance Period (8 weeks).
Change From Baseline in EEG Spike Rate
Tidsramme: Baseline through Part A Maintenance Period (Weeks 1 through 8).

Change from Baseline in electroencephalogram (EEG) spike rate, expressed as spikes per hour, during the Part A Maintenance Period.

Baseline through Part A Maintenance Period (Weeks 1 through 8).
Change From Baseline in EEG Background Activity
Tidsramme: Baseline through Part A Maintenance Period (Weeks 1 through 8).

Change from Baseline in electroencephalogram (EEG) background activity during the Part A Maintenance Period.

Baseline through Part A Maintenance Period (Weeks 1 through 8).
Percentage of Participants With at Least 50% Reduction in Total Countable Seizure Frequency
Tidsramme: Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).

Percentage of participants achieving at least a 50% reduction in total countable seizure frequency per 28 days from Baseline (the last 4 weeks before randomization) to the entire Part A Maintenance Period.

Baseline (last 4 weeks before randomization) to the end of Part A Maintenance Period (8 weeks).
Percentage of Participants With at Least 50% Reduction in Total Seizure Frequency
Tidsramme: Baseline through Part A and Part B, as assessed.

Percentage of participants achieving at least a 50% reduction in total seizure frequency compared with Baseline.

Baseline through Part A and Part B, as assessed.
Percent Change From Baseline in Total Countable Seizure Frequency
Tidsramme: Baseline through Part A and Part B, as assessed.

Percent change from Baseline in total countable seizure frequency normalized to 28 days. Percent change is calculated relative to the Baseline seizure frequency.

Baseline through Part A and Part B, as assessed.
Proportion of Seizure-Free Days
Tidsramme: Baseline through Part A and Part B, as assessed.

Proportion of days without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

Baseline through Part A and Part B, as assessed.
Longest Interval of Seizure Freedom
Tidsramme: Baseline through Part A and Part B, as assessed.

Longest consecutive interval without seizures during the assessment period, based on seizure data recorded in the daily eDiary.

Baseline through Part A and Part B, as assessed.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Michelle Pritikin, GRIN Therapeutics, Inc.
  • Studieleder: Aneeta Saxena, GRIN Therapeutics, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. oktober 2027

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

5. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • RAD-GRIN-102

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere